Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.

Jacob GadwaThomas E BickettLaurel B DarraghMichael William KnitzShilpa BhatiaMiles PiperBenjamin Van CourtShiv BhuvaneDiemmy NguyenVaruna NangiaEmily K KleczkoRaphael A NemenoffSana D Karam

Published in: Journal for immunotherapy of cancer (2021)

Our data establish Tregs as a pro-tumorigenic driver during complement inhibition and provide evidence that targeted C3a and C5a receptor inhibition may add therapeutic advantage when coupled with anti-Treg therapy.

Keyphrases

transcription factor
electronic health record
cancer therapy
big data
stem cells
binding protein
mesenchymal stem cells
drug delivery